ACSL4 and hepatocellular carcinoma: In cholangiocarcinoma, the infiltration level of immune cells is associated with ACSL4 levels, making ACSL4 a potential novel biomarker for cholangiocarcinoma.[18] In patients with pulmonary nodules, serum ACSL4 levels are significantly lower in malignant nodule patients compared to those with benign nodules.[19] In the treatment of hepatocellular carcinoma, ACSL4 is crucial for sorafenib-induced ferroptosis and can be used to predict hepatocellular carcinoma sensitivity to sorafenib.[20] However, no studies have reported the clinical significance of serum ACSL4 in PCa patients.